TGF-β1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancer

Abstract

The transforming growth factor β1 (TGF-β1) and CD8-positive T cells are two important immune factors that function at opposite directions. The purpose of this study was to verify the relationship between the two factors and their associations with long-term effects of adjuvant chemotherapy or endocrine therapy in breast cancer. Expression of TGF-β1 precursor and CD8 was immunohistochemically detected on surgically-obtained tumor samples of 130 (stage I–III) invasive breast carcinomas from Chinese subjects, who were followed up for a mean time of 112 months. Interstitial CD8-positive cells and TGF-β1 precursor-positive cells adjacent to tumor nests were counted. Infiltration of CD8-positive lymphocytes into tumor nests and TGF-β1 precursor expression in tumor cells were observed and survival analysis was performed. Our results showed that density of interstitial CD8-positive lymphocytes was an independent adverse prognostic factor for distant disease-free survival (DDFS) (HR=8.416, 95% CI=1.636–43.292, P=0.011) in hormone receptor-positive patients who were on adjuvant endocrine therapy. For breast cancer patients who did not receive adjuvant chemotherapy, those without infiltration of CD8-positive cells into tumor nests had a shorter overall survival (OS) than their counterparts with CD8-positive cell infiltration into tumor nests (Log-Rank, P=0.003). But OS of patients without infiltration of CD8-positive cells into tumor nests was significantly prolonged by adjuvant chemotherapy (Log-Rank, P=0.013) and paralleled that of patients with CD8-positive cell infiltration. Although OS was shorter in the tumor cell TGF-β1 precursor (t-TGF-β1-pre)-positive patients than in the negative patients in patients without recieiving chemotherapy (P=0.053), OS of t-TGF-β1-pre-positive patients was significantly prolonged by adjuvant chemotherapy (P=0.035) and was longer than that of t-TGF-β1-pre-negative patients. Analysis showed that t-TGF-β1-pre was an independent positive prognostic factor for DDFS (HR=0.392 95% CI=0.157–0.978, P=0.045) in patients who received adjuvant chemotherapy. This study suggested that density of interstitial CD8-positive lymphocytes was of prognostic value in hormone receptor-positive patients who received adjuvant endocrine therapy. Our study verified that adverse immunologic signatures consisting of absence of CD8-positive cells in tumor nests or expression of TGF-β1 precursor in tumor cells in breast cancer were associated with worse prognosis and significantly improved long-term survival with adjuvant chemotherapy, respectively.

Keywords

CD8 / TGF-β1 / breast cancer / adjuvant endocrine therapy / adjuvant chemotherapy / disease-free survival / distant disease-free survival / overall survival

References

[1] MLC, MJP, LG, et al.. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA, 2005, 102(2): 419-424

[2] PBO, BD, MB, et al.. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4.T cells to T-regulatory cells. Cancer Res, 2011, 71(10): 3505-3515

[3] LX, WX, ZW, et al.. In situ prior proliferation of CD4+ CCR6+ regulatory T cells facilitated by TGF-β secreting DCs is crucial for their enrichment and suppression in tumor immunity. PLoS One, 2011, 6(5): e20282

[4] JY, MW, BB, et al.. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity, 2006, 24(5): 575-590

[5] LY, JH, XR, et al.. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell, 2008, 13(1): 23-35

[6] DL, KM, Van EO, et al.. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol, 2011, 55(7–9): 861-867

[7] SPH, MHY, KFT, et al.. Hypoxia-induced secretion of TGF-beta 1 in mesenchymal stem cell promotes breast cancer cell progression. Cell Transplant, 2013, 22(10): 1869-1882

[8] GF, NS-F. CD8+ T suppressor cells are back to the game: are they players in autoimmunity?. Autoimmun Rev, 2002, 1(5): 279-283

[9] AMM, MH, JB, et al.. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer, 2008, 99(7): 1013-1019

[10] AHL, LCH, LGB, et al.. Angiogenesis and inflammation in ductal carcinoma in situ of the breast. J Pathol, 1997, 181(2): 200-206

[11] AR, TK, CL, et al.. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res, 2011, 13(5): R97

[12] GF, NB, FP, et al.. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med, 2008, 14(5): 518-527

[13] SMM, ECP, DGP, et al.. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol, 2011, 29(15): 1949-1955

[14] SL, JL, SL, et al.. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res, 2012, 14(2): R48

[15] DGD, DJB, ER. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov, 201154-67

[16] NRW, KM, PTT, et al.. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res, 2011, 13(6): R126

[17] SL, LA, LA, et al.. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res, 2008, 14(8): 2413-2420

[18] AR, UH, LP, et al.. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res, 2009, 11(2): R15

[19] LAE. Chemoimmunotherapy. Cancer J, 2010, 16(4): 295-303

[20] DP, XHZ, QW, et al.. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell, 2008, 133(1): 66-77

[21] CLA, SDH, ARW, et al.. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest, 1993, 92(6): 2569-2576

[22] JEB, SRM, SSC, et al.. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br J Cancer, 2009, 101(4): 666-672

[23] KI, YM, SK, et al.. Inhibition of dendritic cell migration by transforming growth factor-β1 increases tumor-draining lymph node metastasis. J Exp Clin Cancer Res, 2012, 31: 3

[24] GTL, JHH, CK, et al.. Effect of dominant negative transforming growth factor-beta receptor type II on cytotoxic activity of RAW 264.7, a murine macrophage cell line. Cancer Res, 2007, 67(14): 6717-6724